MovDisordV3, PascalFrancis, Checkpoint, bibRecord, 001C85

Toward future therapies in progressive supranuclear palsy

Identifieur interne : 001C85 ( PascalFrancis/Checkpoint ); précédent : 001C84; suivant : 001C86

Toward future therapies in progressive supranuclear palsy

Auteurs : David J. Burn [Royaume-Uni] ; Naomi M. Warren [Royaume-Uni]

Source :

Movement disorders [ 0885-3185 ] ; 2005.

RBID : Pascal:05-0457452

Descripteurs français

Pascal (Inist)
- Système nerveux pathologie, Traitement, Facteur trophique.

English descriptors

KwdEn :
- Nervous system diseases, Treatment, Trophic factor.

Abstract

There is a stern therapeutic challenge for progressive supranuclear palsy (PSP) that has not yet been met. The lack of randomized, controlled trials and negative outcomes from the vast majority of studies make it impossible to set therapeutic standards, or to give clear recommendations. We review progress to date in this area and briefly consider future potential therapeutic strategies.

Affiliations:

Royaume-Uni

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 001D80
to stream PascalFrancis, to step Curation: 000F41

Links to Exploration step

Pascal:05-0457452

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Toward future therapies in progressive supranuclear palsy</title>
<author><name sortKey="Burn, David J" sort="Burn, David J" uniqKey="Burn D" first="David J." last="Burn">David J. Burn</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Regional Neurosciences Centre, Newcastle General Hospital and Institute for Ageing and Health, University of Newcastle upon Tyne</s1>
<s2>Newcastle upon Tyne</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Newcastle upon Tyne</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Warren, Naomi M" sort="Warren, Naomi M" uniqKey="Warren N" first="Naomi M." last="Warren">Naomi M. Warren</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Regional Neurosciences Centre, Newcastle General Hospital and Institute for Ageing and Health, University of Newcastle upon Tyne</s1>
<s2>Newcastle upon Tyne</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Newcastle upon Tyne</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">05-0457452</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 05-0457452 INIST</idno>
<idno type="RBID">Pascal:05-0457452</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001D80</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000F41</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001C85</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Toward future therapies in progressive supranuclear palsy</title>
<author><name sortKey="Burn, David J" sort="Burn, David J" uniqKey="Burn D" first="David J." last="Burn">David J. Burn</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Regional Neurosciences Centre, Newcastle General Hospital and Institute for Ageing and Health, University of Newcastle upon Tyne</s1>
<s2>Newcastle upon Tyne</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Newcastle upon Tyne</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Warren, Naomi M" sort="Warren, Naomi M" uniqKey="Warren N" first="Naomi M." last="Warren">Naomi M. Warren</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Regional Neurosciences Centre, Newcastle General Hospital and Institute for Ageing and Health, University of Newcastle upon Tyne</s1>
<s2>Newcastle upon Tyne</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Newcastle upon Tyne</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Nervous system diseases</term>
<term>Treatment</term>
<term>Trophic factor</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Traitement</term>
<term>Facteur trophique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">There is a stern therapeutic challenge for progressive supranuclear palsy (PSP) that has not yet been met. The lack of randomized, controlled trials and negative outcomes from the vast majority of studies make it impossible to set therapeutic standards, or to give clear recommendations. We review progress to date in this area and briefly consider future potential therapeutic strategies.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>20</s2>
</fA05>
<fA06><s3>SUP12</s3>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Toward future therapies in progressive supranuclear palsy</s1>
</fA08>
<fA09 i1="01" i2="1" l="ENG"><s1>Atypical Parkinsonian Disorders</s1>
</fA09>
<fA11 i1="01" i2="1"><s1>BURN (David J.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>WARREN (Naomi M.)</s1>
</fA11>
<fA12 i1="01" i2="1"><s1>POEWE (Werner)</s1>
<s9>ed.</s9>
</fA12>
<fA12 i1="02" i2="1"><s1>WENNING (Gregor K.)</s1>
<s9>ed.</s9>
</fA12>
<fA14 i1="01"><s1>Department of Neurology, Regional Neurosciences Centre, Newcastle General Hospital and Institute for Ageing and Health, University of Newcastle upon Tyne</s1>
<s2>Newcastle upon Tyne</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</fA14>
<fA15 i1="01"><s1>Department of Neurology, Medical University Innsbruck</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</fA15>
<fA20><s2>S92-S98</s2>
</fA20>
<fA21><s1>2005</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000132714250140</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2005 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>71 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>05-0457452</s0>
</fA47>
<fA60><s1>P</s1>
<s2>C</s2>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>There is a stern therapeutic challenge for progressive supranuclear palsy (PSP) that has not yet been met. The lack of randomized, controlled trials and negative outcomes from the vast majority of studies make it impossible to set therapeutic standards, or to give clear recommendations. We review progress to date in this area and briefly consider future potential therapeutic strategies.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B02Q</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Traitement</s0>
<s5>09</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Treatment</s0>
<s5>09</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Facteur trophique</s0>
<s5>10</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Trophic factor</s0>
<s5>10</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Factor trófico</s0>
<s5>10</s5>
</fC03>
<fN21><s1>318</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
<pR><fA30 i1="01" i2="1" l="ENG"><s1>Atypical Parkinsonian Disorders - From Protein Dysfunction to Therapeutic Intervention. International Meeting</s1>
<s3>Innsbruck AUT</s3>
<s4>2003-02-19</s4>
</fA30>
</pR>
</standard>
</inist>
<affiliations><list><country><li>Royaume-Uni</li>
</country>
</list>
<tree><country name="Royaume-Uni"><noRegion><name sortKey="Burn, David J" sort="Burn, David J" uniqKey="Burn D" first="David J." last="Burn">David J. Burn</name>
</noRegion>
<name sortKey="Warren, Naomi M" sort="Warren, Naomi M" uniqKey="Warren N" first="Naomi M." last="Warren">Naomi M. Warren</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C85 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 001C85 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Checkpoint
   |type=    RBID
   |clé=     Pascal:05-0457452
   |texte=   Toward future therapies in progressive supranuclear palsy
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Toward future therapies in progressive supranuclear palsy

Toward future therapies in progressive supranuclear palsy

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri